| S. No. |
Antimicrobial |
Control |
Treated |
| 1 |
Amikacin |
≤16 |
≤16 |
| 2 |
Amoxicillin/k-clavulanate |
≤8/4 |
≤8/4 |
| 3 |
Ampicillin/sulbactam |
16/8 |
≤8/4 |
| 4 |
Ampicillin |
>16 |
>16 |
| 5 |
Aztreonam |
≤8 |
≤8 |
| 6 |
Cefazolin |
≤8 |
≤8 |
| 7 |
Cefepime |
≤8 |
≤8 |
| 8 |
Cefotaxime |
≤8 |
≤8 |
| 9 |
Cefotetan |
≤16 |
≤16 |
| 10 |
Cefoxitin |
≤8 |
≤8 |
| 11 |
Ceftazidime |
≤8 |
≤8 |
| 12 |
Ceftriaxone |
≤8 |
≤8 |
| 13 |
Cefuroxime |
≤4 |
≤4 |
| 14 |
Cephalothin |
≤8 |
16 |
| 15 |
Chloramphenicol |
16 |
≤8 |
| 16 |
Ciprofloxacin |
≤1 |
≤1 |
| 17 |
ESBL-a Scrn |
≤4 |
≤4 |
| 18 |
ESBL-b Scrn |
≤1 |
≤1 |
| 19 |
Gatifloxacin |
≤2 |
≤2 |
| 20 |
Gentamicin |
≤4 |
≤4 |
| 21 |
Imipenem |
≤4 |
≤4 |
| 22 |
Levofloxacin |
≤2 |
≤2 |
| 23 |
Meropenem |
≤4 |
≤4 |
| 24 |
Moxifloxacin |
≤2 |
≤2 |
| 25 |
Nitrofurantoin |
≤32 |
≤32 |
| 26 |
Norfloxacin |
≤4 |
≤4 |
| 27 |
Piperacillin/tazobactam |
≤16 |
≤16 |
| 28 |
Piperacillin |
64 |
64 |
| 29 |
Tetracycline |
≤4 |
≤4 |
| 30 |
Ticarcillin/k-clavulanate |
≤16 |
≤16 |
| 31 |
Tobramycin |
≤4 |
≤4 |
| 32 |
Trimethoprim/sulfamethoxazole |
≤2/38 |
≤2/38 |
| MIC values are presented in µg/mL;ESBL: Suspected extended-spectrum β-lactamases a, b screen |
|
